Identification of novel RB1 genetic variants in Retinoblastoma patients and their impact on clinical outcome. (2nd January 2022)

• Record Type: Journal Article
• Authors: Manukonda, Radhika; Pujar, Akhilesh; Ramappa, George; Vemuganti, Geeta K; Kaliki, Swathi
• Is Part Of: Ophthalmic genetics. Volume 43:Number 1(2022)
• Page Start: 64
• Page End: 72
• Publication Date: 2022-01-02
• Subjects: Retinoblastoma -- RB1 gene -- germline mutation -- genetic variants -- clinical outcome -- genetic testing -- tumor recurrence; Eye -- Diseases -- Genetic aspects -- Periodicals; Eye Diseases -- genetics -- Periodicals; Eye Diseases -- in infancy & childhood -- Periodicals; 617.7
• DOI: 10.1080/13816810.2021.1989602
• Languages: English
• ISSNs: 1381-6810

Abstract

ABSTRACT: Background: Retinoblastoma (RB) is an intraocular childhood cancer develops due to inactivation of RB1 gene. Identification of RB1 genetic variants, correlating and confirming genetic test results with clinical outcomes are crucial for effective RB management. Methods: Retrospective study of 62 RB patients and 14 family members who underwent genetic testing either by next generation sequencing (NGS) or multiplex ligation-dependent probe amplification (MLPA) or by both for screening RB1 germline mutations present in peripheral blood. Mutational outcomes were correlated with clinical outcomes evaluated over a follow-up period of 12 months. Results: Of the 62 patients, 35 (56%) had bilateral RB and 27 (44%) had unilateral RB. Out of 24 (52%) variants detected by NGS, 9 (37.5%) were novel and 15 (62.5%) were known in 46 probands. Six (18%) gross deletions were detected by MLPA in 34 probands. The mutation detection rate by NGS and MLPA in unilateral cases was 15% ( n = 4) and 74% ( n = 26) in bilateral cases. In patients with RB1 genetic mutations versus those without, the rate of primary enucleation (7 (12%) vs 18 (44%) eyes; p = .0008) was inversely proportional to tumor recurrence (25 (45%) vs 6 (15%) eyes; p = .002). There was no difference in the rate of globe salvage and metastasis, over a mean follow-up period of 12 months. Conclusion: The mutations screening is important for risk assessment in future siblings and offspring of RB patients and most important in unilateral RB for determining if hereditary or not hereditary RB. Its role in predicting clinical outcomes is yet to be determined.